{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"47"}],"units":"Participants"}],"description":"When calculating the incidence of AEs, each adverse event (AE) (as defined by NCI CTCAE v4.03) will be counted only once for a given subject.","groups":[{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG000","title":"Cohort A: MSI Positive Colorectal Cancer"},{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG001","title":"Cohort B: MSI Negative Colorectal Cancer"},{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG002","title":"Cohort C: MSI Positive Non-Colorectal Cancer"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"28 months","title":"Number of Patients Experiencing a Grade 3 or Above Treatment-related Toxicity","type":"SECONDARY","unitOfMeasure":"Participants"}